19 Mid Cap Stocks Just Made New 52-Week Highs
A new list of market leaders is heavily concentrated in one particular part of the economy.
Biogen (BIIB), with a market value of about $32.6 billion, is the largest of 19 Mid Cap stocks from the Russell 3000 at a 52-week high today. The list is overwhelmingly tilted toward a single area of the market: of the 19 names, Health Care accounts for 11 names. This raises a critical question about whether the underlying business performance is as uniform as the price action. The 10 largest of these companies are detailed below.
The Biggest Names On The List
The table below shows the 10 largest of the 19 names, sorted by market capitalization, with returns over four windows:
- The 52-Week-Low List: 5 Names On Wednesday
- 22 S&P 500 Stocks Hit 52-Week Highs On Wednesday
- S&P 500 Movers | Winners: MRNA, EL, MRK | Losers: STX, STLD, WDC
- Where The Buying Ran Strongest: 46 Small Cap Stocks At 52-Week Highs
- The 52-Week-High List: 18 Large Cap Names On Wednesday
- Market Movers | Winners: MRNA, PURR, MRVI | Losers: LZB, TMS
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| BIIB | $32.61 Bil | 4.2% | 6.1% | 9.1% | 63.0% |
| LH | $27.2 Bil | 2.6% | 2.2% | 18.3% | 23.5% |
| DGX | $26.84 Bil | 2.3% | 1.7% | 16.9% | 37.5% |
| ROIV | $26.83 Bil | 0.1% | 3.4% | 7.0% | 216.7% |
| PR | $18.7 Bil | 3.0% | 7.3% | 9.7% | 80.0% |
| OVV | $18.36 Bil | 0.8% | 3.7% | 10.4% | 71.8% |
| JLL | $18.28 Bil | 5.2% | 7.6% | 20.3% | 33.2% |
| NLY | $17.16 Bil | 1.5% | 2.7% | 4.8% | 31.1% |
| CRL | $14.2 Bil | 3.9% | 2.0% | 32.2% | 84.7% |
| RVTY | $13.36 Bil | 5.0% | 1.3% | 8.1% | 33.5% |
Are these Health Care highs all built on growth?
Not uniformly. A look inside the numbers shows different stories even among direct industry peers. Labcorp (LH) hit its high alongside revenue that grew 6.4% over the last twelve months and an operating margin of 11.4%. Quest Diagnostics (DGX) shows a similar profile, with revenue that grew 9.9% and an operating margin of 14.1%.
The largest name on the list, Biogen (BIIB), presents a different picture. Its revenue grew just 0.3% over the last twelve months, though it maintained an operating margin of 19.3%. The price strength is not matched by top-line expansion in every case.
A new high is a starting point for research, not a conclusion.
A 52-week-high list is a useful screen for strength. Stocks that are working often continue to work. But a price is not a verdict on a business, and a new high is no guarantee of future returns. The disciplined next step is to investigate whether the company’s financial results can support its new valuation. The price has made its move; the work is to see if the business is earning it.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 11 of the 19 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like IBB is one way to own the group’s strength without betting on which single name leads it from here.
New Highs Fade. Discipline Compounds
Some of the names on this list will keep setting highs for years, and some are at the top of their run right now. Sorting one from the other, name by name, every day, is the work most investors never keep up with.
That sorting is what the Trefis High Quality (HQ) Portfolio does systematically: about 30 quality businesses screened for the fundamentals that sustain a run, held with rules instead of excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the high list for ideas; use the portfolio for the compounding.